Patents by Inventor Steven A. Rosenberg

Steven A. Rosenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T cell receptors and related materials and methods of use
    Patent number: 9688739
    Abstract: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: June 27, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven A. Rosenberg, Richard A. Morgan, Timothy L. Frankel
  • ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER
    Publication number: 20170174771
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • METHODS OF GROWING TUMOR INFILTRATING LYMPHOCYTES IN GAS-PERMEABLE CONTAINERS
    Publication number: 20170152478
    Abstract: An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 1, 2017
    Applicants: The USA, as represented by the Secretary, Department of Health and Human Service, Wilson Wolf Manufacturing Corporation
    Inventors: Steven A. Rosenberg, Mark E. Dudley, David Stroncek, Marianna Sabatino, Jianjian Jin, Robert Somerville, John R. Wilson
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS
    Publication number: 20170145070
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: May 29, 2015
    Publication date: May 25, 2017
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Methods of Preparing T Cells for T Cell Therapy
    Publication number: 20170136063
    Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
    Type: Application
    Filed: October 20, 2016
    Publication date: May 18, 2017
    Applicants: Kite Pharma, Inc., National Cancer Institute
    Inventors: Arianne Perez, Marianna Sabatino, Steven A. Rosenberg, Nicholas P. Restifo
  • Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
    Patent number: 9624306
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: April 18, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • MURINE ANTI-NY-ESO-1 T CELL RECEPTORS
    Publication number: 20170029483
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 2, 2017
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
    Patent number: 9522955
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: December 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven A. Rosenberg, Dhanalakshmi Chinnasamy
  • GP100-specific T cell receptors and related materials and methods of use
    Patent number: 9522948
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN, NY ESO-1
    Publication number: 20160354409
    Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
  • Methods of Conditioning Patients for T Cell Therapy
    Publication number: 20160346326
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Applicants: Kite Pharma, Inc., National Cancer Institute
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • ANTI-NY-BR-1 POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20160333422
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize NY-BR-1 are disclosed. Chimeric antigen receptors (CARs), anti-NY-BR-1 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 17, 2016
    Inventors: Steven A. Feldman, Steven A. Rosenberg
  • Murine anti-NY-ESO-1 T cell receptors
    Patent number: 9487573
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: November 8, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20160279196
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: April 19, 2016
    Publication date: September 29, 2016
    Inventors: Richard A. Morgan, Nachimuthu Chinnasamy, Steven A. Rosenberg
  • MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
    Patent number: 9447144
    Abstract: The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4+ T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: September 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rong-Fu Wang, Steven A. Rosenberg, Gang Zeng
  • ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER
    Publication number: 20160200819
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Application
    Filed: January 13, 2016
    Publication date: July 14, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • Anti-mesothelin chimeric antigen receptors
    Patent number: 9359447
    Abstract: The invention provides a chimeric antigen receptor (CAR) (a) an antigen binding domain of HN1 or SS, a transmembrane domain, and an intracellular T cell signaling domain, or (b) an antigen binding domain of SS1, a transmembrane domain, an intracellular T cell signaling domain, and a granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor 2 leader. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: June 7, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven A. Feldman, Steven A. Rosenberg, Ira H. Pastan
  • ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS
    Publication number: 20160152681
    Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Application
    Filed: July 14, 2014
    Publication date: June 2, 2016
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS
    Publication number: 20160144018
    Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
    Type: Application
    Filed: July 14, 2014
    Publication date: May 26, 2016
    Applicant: The United States of America, as represented by The Secretary, Department of Health and Human Serv
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Anti-SSX-2 T cell receptors and related materials and methods of use
    Patent number: 9345748
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: May 24, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard A. Morgan, Nachimuthu Chinnasamy, Dhanalakshmi Chinnasamy, Steven A. Rosenberg